SCHEMBL4239937

SCHEMBL4239937

Cc1nc2c3c(c(C(=O)NCCO)cc2n1C)CCC1(Cc2ccccc2C1)N3

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 2/20 0.34
CCNA2 P20248 1/20 0.34
CCNA1 P78396 1/20 0.34
LMNA P02545 1/20 0.34
KDM4E B2RXH2 4/20 0.33
ALDH1A1 P00352 3/20 0.33
MAPT P10636 2/20 0.33
MEN1 O00255 1/20 0.33
CACNA1B Q00975 1/20 0.33
APBA1 Q02410 1/20 0.33
KMT2A Q03164 1/20 0.33
CASP1 P29466 1/20 0.33
CASP7 P55210 1/20 0.33
ACSS2 Q9NR19 2/20 0.33
HPGD P15428 2/20 0.33
GAA P10253 1/20 0.33
HIF1A Q16665 1/20 0.33
CGAS Q8N884 1/20 0.32
AURKA O14965 1/20 0.32
OPRL1 P41146 3/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4241781 0.95 OPRL1 (0.34) CDK2CCNA2CCNA1KDM4EALDH1A1
SCHEMBL4242410 0.92 ALDH1A1 (0.36) KDM4EALDH1A1MAPTKMT2AHPGD
SCHEMBL4235958 0.91 CHIA (0.32) CDK2CCNA2KDM4EHSD17B10HCN1
Hydrochloric Acid SCHEMBL4245930 0.91 ALDH1A1 (0.35) KDM4EALDH1A1MAPTKMT2AHPGD
SCHEMBL4241846 0.90 HCN1 (0.30) HCN1HCN4
Malonic Acid SCHEMBL4246390 0.89 ALDH1A1 (0.34) KDM4EALDH1A1MAPTKMT2AHPGD
SCHEMBL4240859 0.88 CRBN (0.32) CDK2CCNA2CCNA1LMNAKDM4E
SCHEMBL4240110 0.88 ACSS2 (0.35) MEN1KMT2AACSS2SMN1; SMN2
Hydrochloric Acid SCHEMBL4242508 0.88 CRBN (0.32) CDK2CCNA2CCNA1SMN1; SMN2
Fumaric Acid SCHEMBL4244556 0.87 KMT2A (0.33) KDM4EALDH1A1MAPTKMT2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090093473-A1 Spiro-benzimidazoles as inhibitors of gastric acid secretion NYCOMED GMBH (DE) 2009-04-09 US claimed
EP-1899338-A1 SPIRO-BENZIMIDAZOLES AS INHIBITORS OF GASTRIC ACID SECRETION Nycomed GmbH (DE) 2008-03-19 EP claimed
WO-2006134111-A1 SPIRO-BENZIMIDAZOLES AS INHIBITORS OF GASTRIC ACID SECRETION NYCOMED GMBH (DE) 2006-12-21 WO claimed
US-20090093473-A1 Spiro-benzimidazoles as inhibitors of gastric acid secretion NYCOMED GMBH (DE) 2009-04-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090093473-A1 Spiro-benzimidazoles as inhibitors of gastric acid secretion GIPR, PGC, SLC10A2 CDK2 1022/4885CCNA2 2980/4885CCNA1 2730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.